Check the time stamp on this data. Updated AI-Generated Signals for Catalyst Pharmaceuticals Inc. (CPRX) available here: CPRX ...

Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

This was the stock's second consecutive day of losses.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...

Catalyst Pharmaceuticals Inc. closed 4.99% short of its 52-week high of $24.27, which the company achieved on November 8th.

Truist Financial analyst Joon Lee maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today. The company’s shares closed ...

Evitar Corte warned of market crash risk four times since 2000. It identified the Internet Debacle before it happened. It identified the Credit Crisis before it happened. It identified the Corona ...

StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday. CPRX has been the ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 in a note issued to investors on Friday,Benzinga reports. The brokerage ...